Dattoli Cancer Center

The Dattoli Cancer Center has the singular goal of treating and curing its patients’ prostate cancer without damaging their lifestyles. The center offers an alternative to prostate surgery with an unmatched combination of leading-edge diagnostic and treatment technology including 3-D Color-Flow Doppler Ultrasound, Helical CT Imaging, Varian IG-IMRT Radiation Therapy with SonArray Ultrasound Guided Positioning, Theraseed Palladium-103 Brachytherapy and Dynamic Biological Adaptive Fusion capabilities. The center boasts the longest standing and largest study in existence (now 16 years) of non-surgical prostate cancer treatment results which makes the Dattoli Cancer Center the top choice for men from around the world.

placement of two senior debt facilities

The undersigned acted as the financial advisor to Dattoli Cancer Center & Brachytherapy Research Institute for these transactions.

Back to Transactions

Client Testimonials

"Hyde Park’s team guided us through the process, providing us with a number of high quality counter-parties, and supported us through the transaction structuring, negotiation and due diligence. We are very pleased with the outcome and excited for the future of DTS.”
Allen Ibaugh, Co-Founder and CEO of Data Transfer Solutions
“We enjoyed working with Hyde Park Capital and appreciated their M&A expertise in the technology services sector and their help on this important transaction.”
Chris Toepke, CEO of Trifecta
“We very much appreciated the assistance of Hyde Park Capital on this strategic acquisition for ITE. Their M&A experience was quite helpful to our team and the overall process and assured the deal was well executed and we got it closed on schedule.”
Scott Dols, CEO of Industrial Truck & Equipment, LLC